Volta Medical

Volta Medical, headquartered in Marseille, France, focuses on developing advanced medical devices for the cardiovascular sector, aiming to enhance patient care through innovative solutions in cardiac rhythm management. Founded in 2016, Volta Medical operates in the cardiovascular medical device space, creating products for cardiac rhythm management. The company has engaged in four notable funding rounds, with the latest being a Series B round in January 2023, where they raised EUR 36. 00 mn led by Vensana Capital.

The firm has no known subsidiaries. The company was co-founded by Clement Bars, Eng Abo-Aldouh, and Jerome Kalifa, with Théophile Durdez currently serving as CEO. Volta Medical specializes in developing advanced medical devices designed to enhance patient care in the cardiovascular sector. Their core product offerings focus on innovative solutions for cardiac rhythm management, leveraging proprietary technologies to improve the diagnosis and treatment of arrhythmias.

The primary end-users of these products include healthcare providers such as hospitals and specialty clinics, where they aim to address critical needs in cardiac monitoring and intervention. By providing sophisticated tools for clinicians, Volta Medical targets a market composed of cardiology departments across the United States, facilitating improved patient outcomes through real-time data analysis and streamlined workflows. Their devices are engineered to integrate with existing healthcare systems, thereby enhancing usability and accessibility for medical professionals in the field. Volta Medical's revenue model is structured around direct sales to healthcare institutions, focusing on B2B transactions within the medical device industry.

The company's flagship products, which are integral to their revenue generation, are sold through a system of partnerships with healthcare providers that facilitate bulk purchasing agreements. These partnerships enable healthcare facilities to access Volta Medical’s innovative technologies while benefiting from structured pricing plans tailored to institutional budgets. Revenue is further supplemented by potential service agreements and maintenance contracts associated with the medical devices, ensuring ongoing support and functionality. The financial transactions executed by the company reflect a commitment to delivering value to their clients while maintaining a sustainable business model within the competitive landscape of medical technology.

In January 2023, Volta Medical raised EUR 36. 00 mn in Series B funding led by Vensana Capital, which will be used to accelerate new product development, support additional clinical trials, and initiate sales in the US while gaining further regulatory approval. The company plans to expand its market reach, particularly targeting the US healthcare sector, with new product launches expected in the coming years.